WO2008005217A3 - Iron(ii)-containing treatments for hyperphosphatemia - Google Patents

Iron(ii)-containing treatments for hyperphosphatemia Download PDF

Info

Publication number
WO2008005217A3
WO2008005217A3 PCT/US2007/014688 US2007014688W WO2008005217A3 WO 2008005217 A3 WO2008005217 A3 WO 2008005217A3 US 2007014688 W US2007014688 W US 2007014688W WO 2008005217 A3 WO2008005217 A3 WO 2008005217A3
Authority
WO
WIPO (PCT)
Prior art keywords
iron
pharmaceutically acceptable
hyperphosphatemia
compound
ferrous
Prior art date
Application number
PCT/US2007/014688
Other languages
French (fr)
Other versions
WO2008005217A2 (en
Inventor
Chad C Huval
Pradeep K Dhal
Stephen Randall Holmes-Farley
Original Assignee
Genzyme Corp
Chad C Huval
Pradeep K Dhal
Stephen Randall Holmes-Farley
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp, Chad C Huval, Pradeep K Dhal, Stephen Randall Holmes-Farley filed Critical Genzyme Corp
Priority to US12/307,420 priority Critical patent/US20100135950A1/en
Priority to JP2009518197A priority patent/JP2009542653A/en
Priority to EP07796408A priority patent/EP2043627A2/en
Publication of WO2008005217A2 publication Critical patent/WO2008005217A2/en
Publication of WO2008005217A3 publication Critical patent/WO2008005217A3/en
Priority to US13/534,672 priority patent/US20130243720A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A pharmaceutical composition comprises a pharmaceutically acceptable ferrous iron compound; an amine polymer or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. Alternatively, a pharmaceutica composition comprises a pharmaceutically acceptable ferrous iron compound and pharmaceutically acceptable carrier, wherein the ferrous iron compound is selecte from the group consisting of iron(II) acetate, iron(II) citrate, iron(II) ascorbate, iron(II) oxalate, iron(II) oxide, iron(II) carbonate, iron(II) carbonate saccharated, iron(II) formate, iron(II) sulfate, iron(II) chloride, iron(II) acetylacetonate and combinations thereof. A method of treating a subject with hyperphosphatemia comprises administering to the subject an effective amount of a pharmaceutical composition as described above.
PCT/US2007/014688 2006-07-05 2007-06-25 Iron(ii)-containing treatments for hyperphosphatemia WO2008005217A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US12/307,420 US20100135950A1 (en) 2006-07-05 2007-06-25 Iron(II)-Containing Treatments for Hyperphosphatemia
JP2009518197A JP2009542653A (en) 2006-07-05 2007-06-25 Iron (II) containing therapeutic agent for hyperphosphatemia
EP07796408A EP2043627A2 (en) 2006-07-05 2007-06-25 Iron(ii)-containing treatments for hyperphosphatemia
US13/534,672 US20130243720A1 (en) 2006-07-05 2012-06-27 Iron(II)-Containing A Treatments for Hyperphosphatemia

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81872706P 2006-07-05 2006-07-05
US60/818,727 2006-07-05

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/534,672 Continuation US20130243720A1 (en) 2006-07-05 2012-06-27 Iron(II)-Containing A Treatments for Hyperphosphatemia

Publications (2)

Publication Number Publication Date
WO2008005217A2 WO2008005217A2 (en) 2008-01-10
WO2008005217A3 true WO2008005217A3 (en) 2008-02-21

Family

ID=38772059

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/014688 WO2008005217A2 (en) 2006-07-05 2007-06-25 Iron(ii)-containing treatments for hyperphosphatemia

Country Status (4)

Country Link
US (2) US20100135950A1 (en)
EP (1) EP2043627A2 (en)
JP (1) JP2009542653A (en)
WO (1) WO2008005217A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1394299B1 (en) * 2009-05-12 2012-06-06 Chimico Internaz Spa Lab PROCEDURE FOR THE PREPARATION OF SEVELAMER
CN108403678A (en) * 2011-10-12 2018-08-17 思佰益药业股份有限公司 The improvement of chronic kidney disease, prophylactic
WO2013087237A1 (en) * 2011-12-13 2013-06-20 Synthon Bv Purification of sevelamer and related polyallylamines
RU2014128587A (en) * 2011-12-13 2016-02-10 Синтон Б.В. GETTING A SEALAMER WITH A REDUCED ALLYLAMINE CONTENT
LT3003327T (en) 2013-06-05 2017-12-27 Tricida Inc. Proton-binding polymers for oral administration
MX2017007497A (en) 2014-12-10 2017-10-04 Tricida Inc Proton-binding polymers for oral administration.
US20190381024A1 (en) * 2015-10-27 2019-12-19 Medice Arzneimittel Putter Gmbh & Co. Kg Nicotinamide for lowering phosphate levels in hyperphosphatemia
RU2018142943A (en) 2016-05-06 2020-06-08 Трисида, Инк. COMPOSITIONS FOR TREATING ACID-BASIC EQUILIBRIUM DISORDERS
US11266684B2 (en) 2017-11-03 2022-03-08 Tricida, Inc. Compositions for and method of treating acid-base disorders

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB933108A (en) * 1960-02-03 1963-08-08 Haessle Ab Improvements in or relating to pharmaceutical iron preparations
GB2121277A (en) * 1982-06-09 1983-12-21 Dorrian Ray Duncan Barnett Preparations for combating colds and flu, containing iron salt and calcium lactate
EP1457256A1 (en) * 2001-12-21 2004-09-15 Muromachi Chemical Co., Ltd Adsorbent for phosphoric acid
WO2005092039A2 (en) * 2004-03-22 2005-10-06 Ilypsa, Inc. Crosslinked amine polymers
WO2006061336A2 (en) * 2004-12-07 2006-06-15 Vincenzo Savica Oral compositions for absorption of phosphorus compounds

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2456428A (en) * 1944-10-11 1948-12-14 Shell Dev Polyallyl amine and related polymeric amines
US3104205A (en) * 1959-12-17 1963-09-17 Warner Lambert Pharmaceutical Deodorant composition comprising the copper complex of the copolymer of allylamine and methacrylic acid
US3308020A (en) * 1961-09-22 1967-03-07 Merck & Co Inc Compositions and method for binding bile acids in vivo including hypocholesteremics
US3332841A (en) * 1961-10-04 1967-07-25 Lilly Co Eli Method of treating hyperacidity
US3624209A (en) * 1966-12-28 1971-11-30 Bristol Myers Co Composition for treatment of gastro-intestinal disorders
US3980770A (en) * 1971-06-04 1976-09-14 Pharmacia Aktiebolag Polymerization products containing amino groups useful in serum cholesterol level control
US4205064A (en) * 1973-06-11 1980-05-27 Merck & Co., Inc. Bile acid sequestering composition containing poly[{alkyl-(3-ammoniopropyl)imino}-trimethylenedihalides]
US4181718A (en) * 1975-12-29 1980-01-01 Mason Norbert S Polyanion-stabilized aluminum hydrogels
US4071478A (en) * 1976-06-07 1978-01-31 Merck & Co., Inc. Controlled partially cross-linked 3,3-ionenes
US4183918A (en) * 1977-03-08 1980-01-15 Exxon Research & Engineering Co. Detoxifying-medicinal emulsions
US4143130A (en) * 1977-08-29 1979-03-06 Warren-Teed Laboratories, Inc. Method for treating kidney stones
US4247393A (en) * 1979-01-11 1981-01-27 Wallace Richard A Hemodialysis assist device
US4344993A (en) * 1980-09-02 1982-08-17 The Dow Chemical Company Perfluorocarbon-polymeric coatings having low critical surface tensions
US4504640A (en) * 1982-05-19 1985-03-12 Nitto Boseki Co., Ltd. Process for producing monoallylamine polymer
DE3241113A1 (en) * 1982-11-06 1984-05-10 Bayer Ag, 5090 Leverkusen VACCINES WITH INGREDIENTS
JPS6090243A (en) * 1983-10-25 1985-05-21 Nitto Boseki Co Ltd Small spherical crosslinked monoallylamine polymer and its preparation
CA1220897A (en) * 1984-01-11 1987-04-21 Kiyoshi Shimizu Process for producing polymers of monoallylamine
US4631305A (en) * 1985-03-22 1986-12-23 The Upjohn Company Polymeric material as a disintegrant in a compressed tablet
DE3541511A1 (en) * 1985-11-19 1987-05-21 Grace W R Ab PROMOTER FOR PAPER SIZING, METHOD FOR THE PRODUCTION AND USE THEREOF
US6274713B1 (en) * 1989-04-07 2001-08-14 Salutar, Inc. Polychelants
US5236701A (en) * 1989-07-19 1993-08-17 Lowchol Scientific Inc. Ingestible hydrophilic polymeric amines useful for lowering blood cholesterol
US5053423A (en) * 1990-03-22 1991-10-01 Quadra Logic Technologies Inc. Compositions for photodynamic therapy
IE914179A1 (en) * 1990-12-07 1992-06-17 Ici Plc Nitrogen derivatives
US5055197A (en) * 1991-04-05 1991-10-08 Rohm And Haas Company Process for removing residual monomers and oligemers from amine-containing polymers
US5108767A (en) * 1991-06-10 1992-04-28 Abbott Laboratories Liquid nutritional product for persons receiving renal dialysis
EP0580078B1 (en) * 1992-07-22 1997-10-15 Hoechst Aktiengesellschaft Hydrophilic groups containing poly(vinylamine) derivatives, process for their manufacture and use thereof as pharmaceutical compounds, substrates for active substances and foodstuff ingredients
EP0580079B1 (en) * 1992-07-22 1996-12-11 Hoechst Aktiengesellschaft Crosslinked, nitrogen-containing vinyl copolymers, process for their manufacture and use of these compounds
US5302531A (en) * 1992-10-22 1994-04-12 Miles Inc. Composition for the semiquantitative determination of specific gravity of a test sample
US5487888A (en) * 1993-05-20 1996-01-30 Geltex, Inc. Iron-binding polymers for oral administration
US5929184A (en) * 1993-06-02 1999-07-27 Geltex Pharmaceuticals, Inc. Hydrophilic nonamine-containing and amine-containing copolymers and their use as bile acid sequestrants
US5496545A (en) * 1993-08-11 1996-03-05 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
US5667775A (en) * 1993-08-11 1997-09-16 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
US5414068A (en) * 1994-01-24 1995-05-09 Rohm And Haas Company Crosslinked anion exchange particles and method for producing the particles
US5760121A (en) * 1995-06-07 1998-06-02 Amcol International Corporation Intercalates and exfoliates formed with oligomers and polymers and composite materials containing same
CN1230118A (en) * 1996-07-19 1999-09-29 日研化学株式会社 Remedies for hyperphosphatemia
US5753706A (en) * 1996-12-16 1998-05-19 Hsu; Chen Hsing Methods for treating renal failure
GB9720061D0 (en) * 1997-09-19 1997-11-19 Crosfield Joseph & Sons Metal compounds as phosphate binders
US5985938A (en) * 1997-11-05 1999-11-16 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
US6566407B2 (en) * 1997-11-05 2003-05-20 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
EP0949290B1 (en) * 1998-04-09 2006-12-27 Nippon Shokubai Co., Ltd. Crosslinked polymer particle and its production process and use
DE19835467A1 (en) * 1998-08-06 2000-02-17 Elenac Gmbh Solid reactor with antistatic coating for carrying out reactions in the gas phase
US6733780B1 (en) * 1999-10-19 2004-05-11 Genzyme Corporation Direct compression polymer tablet core
US20020054903A1 (en) * 1999-10-19 2002-05-09 Joseph Tyler Direct compression polymer tablet core
JP2004528332A (en) * 2001-04-18 2004-09-16 ジェンザイム コーポレーション Method of treating gout and binding uric acid
WO2002085379A1 (en) * 2001-04-18 2002-10-31 Geltex Pharmaceuticals, Inc. Method for improving vascular access in patients with vascular shunts
KR20040018357A (en) * 2001-04-18 2004-03-03 젠자임 코포레이션 Low salt forms of polyallylamine
AU2002257145B2 (en) * 2001-04-18 2005-06-02 Genzyme Corporation Method for lowering serum glucose
WO2002085380A1 (en) * 2001-04-18 2002-10-31 Geltex Pharmaceuticals, Inc. Method for treating gout and reducing serum uric acid
JP4303595B2 (en) * 2001-12-21 2009-07-29 透 小池 Zinc complexes capable of trapping substances with anionic substituents
US7119120B2 (en) * 2001-12-26 2006-10-10 Genzyme Corporation Phosphate transport inhibitors
US20040115265A1 (en) * 2002-12-11 2004-06-17 Loutfy Benkerrour Multilayered tablet containing pravastatin and aspirin and method
EP1699442A2 (en) * 2003-12-31 2006-09-13 Genzyme Corporation Enteric coated aliphatic amine polymer bile acid sequestrants
US7019085B2 (en) * 2004-08-30 2006-03-28 Albright Robert L Phosphate selective resin and related methods
US7985418B2 (en) * 2004-11-01 2011-07-26 Genzyme Corporation Aliphatic amine polymer salts for tableting
US20060177415A1 (en) * 2004-11-01 2006-08-10 Burke Steven K Once a day formulation for phosphate binders

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB933108A (en) * 1960-02-03 1963-08-08 Haessle Ab Improvements in or relating to pharmaceutical iron preparations
GB2121277A (en) * 1982-06-09 1983-12-21 Dorrian Ray Duncan Barnett Preparations for combating colds and flu, containing iron salt and calcium lactate
EP1457256A1 (en) * 2001-12-21 2004-09-15 Muromachi Chemical Co., Ltd Adsorbent for phosphoric acid
WO2005092039A2 (en) * 2004-03-22 2005-10-06 Ilypsa, Inc. Crosslinked amine polymers
WO2006061336A2 (en) * 2004-12-07 2006-06-15 Vincenzo Savica Oral compositions for absorption of phosphorus compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KURODA S ET AL: "EFFECT OF IRON AS A NEW TYPE OF PHOSPHATE BINDER IN HEMODIALYSIS PATIENTS", JAPANESE JOURNAL OF NEPHROLOGY - NIHON JINZO GAKKAISHI, NIHON JINZO GAKKAI, TOKYO, JP, vol. 8, no. 37, August 1995 (1995-08-01), pages 468 - 473, XP008002871, ISSN: 0385-2385 *

Also Published As

Publication number Publication date
US20130243720A1 (en) 2013-09-19
EP2043627A2 (en) 2009-04-08
JP2009542653A (en) 2009-12-03
WO2008005217A2 (en) 2008-01-10
US20100135950A1 (en) 2010-06-03

Similar Documents

Publication Publication Date Title
WO2008005217A3 (en) Iron(ii)-containing treatments for hyperphosphatemia
WO2011031474A3 (en) Use of metformin in cancer treatment and prevention
MXPA06012865A (en) Permeation enhancing compositions for anticholinergic agents.
WO2008112565A3 (en) Method and composition for treating cancer
WO2009017838A3 (en) Combinations of jak-2 inhibitors and other agents
WO2008075068A3 (en) Acylaminopyrazoles as fgfr inhibitors
WO2008124085A3 (en) Methods of using combinations of mek and jak-2 inhibitors
NZ599284A (en) Combinations of a specific hcv ns5a inhibitor and an hcv ns3 protease inhibitor
WO2010132777A3 (en) Treatment of urinary tract infections with antibacterial aminoglycoside compounds
WO2005046618A3 (en) Methods of treating eczema
BRPI0413746A (en) compound or a n-oxide thereof or pharmaceutically acceptable salt thereof, composition, and method of treating hyperproliferative disorder
BRPI0413785A (en) compound, composition, and method of treating hyperproliferative disorder
CA2854927A1 (en) A two-part pharmaceutical formulation comprising chelating micelles for control release of drug
WO2012006055A3 (en) Compounds and methods for the treatment or prevention of flavivirus infections
WO2006094144A3 (en) Use of rifaximin for the prevention of aspiration pneumonia and/or sepsis
BRPI0413740A (en) compound or a n-oxide thereof or pharmaceutically acceptable salt thereof, composition, and method of treating hyperproliferative disorder
CA2547990A1 (en) Pharmaceutical compositions and methods for insulin treatment
WO2007044180A3 (en) Improved toleration iron supplement compositions
WO2003092629A3 (en) Methods of simultaneously treating mucositis and fungal infection
UA96969C2 (en) Acylaminopyrazoles as fgfr inhibitors
WO2006009893A3 (en) Cancer chemotherapy
WO2011153458A3 (en) Compositions and methods for inhibition of or treatment of dengue virus infection
WO2013061328A3 (en) Methods of treating cancer
WO2007062333A3 (en) New pleuromutilin derivative and its use
WO2003022280A3 (en) 3-glyoxlylamideindoles for treating cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07796408

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2007796408

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2009518197

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

WWE Wipo information: entry into national phase

Ref document number: 12307420

Country of ref document: US